GlobeNewswire

ERYTECH Presents TRYbeCA-1 Trial-in-Progress Poster at the 2019 ASCO GI Annual Meeting

Del

LYON, France and CAMBRIDGE, Mass., Jan. 18, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, announced that a poster entitled “TRYbeCA-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma (NCT03665441)” will be presented today at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in San Francisco. The poster (Abstract # TPS471) will be available at www.erytech.com after presentation at the conference.

In September 2018, the TRYbeCA-1 trial was initiated. The Trial-in-Progress poster will provide an update on the study progress with investigators sites that have been initiated in multiple countries and actively recruiting patients. The trial is planned to enroll approximately 500 patients with second line metastatic pancreatic cancer in 120-130 clinical sites in 12 European countries and the United states. Currently the trial is approved for patients participation in eight selected European countries, and enrolling patients in 21 clinical sites.

Patients who meet the eligibility criteria are randomized 1-to-1 to receive eryaspase in combination with standard chemotherapy (gemcitabine/abraxane or irinotecan-based regimen) or chemotherapy alone until disease progression. The primary endpoint is overall survival. An interim analysis is foreseen when approximately two-thirds of events have occurred.

The launch of the Trybeca-1 Phase 3 trial follows the positive Phase 2b results in the same patient population, that were reported in September 20171. This open-label, multi-center, 2-to-1 randomized study in 141 patients demonstrated significant improvement in both overall survival and progression-free survival. Overall, eryaspase was well tolerated and did not appear to increase the toxicity of the chemotherapy. 

“Patients with advanced pancreatic cancer need new treatment options. As global co-Principal Investigator, I am delighted with the rapid set-up of the study. The Trial-in-Progress poster demonstrates that we are making excellent progress toward the initiation of over 100 centers for TRYbeCA-1 ,” commented Dr. Manuel Hidalgo-Medina, medical oncologist at Beth Israel Deaconess Medical Center in Boston and professor of medicine at Harvard Medical School.  

“The results from our landmark Phase 2b study are highly promising and underscore the importance of targeting tumor metabolism pathways in pancreatic cancer. We are hopeful to provide a novel treatment modality for this highly unmet medical need. We are very pleased that the Phase 3 study is making excellent progress and patient enrollment continues as planned. Our enrolled patients mark the initiation of the trial in Europe. We expect investigator sites in the United States will begin enrolling this quarter,” commented Iman El-Hariry, Chief Medical Officer.

About pancreatic cancer

Pancreatic cancer is a disease in which malignant (cancer) cells are found in the tissues of the pancreas. Every year, there are approximately 150,000 new cases of pancreatic cancer diagnosed in Europe and the United States. Advanced pancreatic cancer is a particularly aggressive cancer, with a five-year survival rate of less than 10%. It is currently the fourth leading cause of cancer death in Europe and the United States and is projected to rise to the second leading cause by 2030. Limited therapeutic options are currently available for this indication, thereby reinforcing the need to develop new therapeutic strategies and rational drug combinations with the aim of improving overall patient outcomes and quality of life.

About ERYTECH and eryaspase (GRASPA®): www.erytech.com

ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates to address markets with high unmet medical needs.

ERYTECH’s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival. The Company’s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cell’s altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in preparations to enter Phase 2 clinical development for the treatment of triple-negative breast cancer. ERYTECH’s next product candidate erymethionase, which consists of methionine-gamma-lyase encapsulated in red blood cells to target methionine-dependent cancers, has demonstrated promising preclinical results and is in preparations to enter Phase 1 clinical development.

ERYTECH is also exploring the use of its ERYCAPS platform for developing cancer immunotherapies (ERYMMUNE) and enzyme therapies (ERYZYME).

ERYTECH produces product candidates at its GMP-approved manufacturing site in Lyon, France, and at the American Red Cross in Philadelphia, USA. A large-scale GMP manufacturing facility is under construction in New Jersey, USA.

ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.

CONTACTS

ERYTECH    
Eric Soyer
CFO & COO
NewCap
Mathilde Bohin / Louis-Victor Delouvrier
Investor relations
Nicolas Merigeau
Media relations

+33 4 78 74 44 38
i nvestors@erytech.com
+33 1 44 71 98 52
erytech@newcap.eu

Forward-looking information

This press release contains forward-looking statements, forecasts and estimates with respect to the clinical results from and the development plans of eryaspase, business and regulatory strategy, expansion of manufacturing capacity and anticipated future performance of ERYTECH and of the market in which it operates. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. All statements contained in this press release other than statements of historical facts are forward-looking statements, including, without limitation, statements regarding the potential of ERYTECH’s product pipeline, its clinical development and regulatory plans for eryaspase, the timing of ERYTECH’s clinical studies and trials and announcements of data from those studies and trials, and the contents and timing of decisions by the FDA and EMA regarding ERYTECH’s product candidates. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond ERYTECH's control. There can be no guarantees with respect to pipeline product candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. Therefore, actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Further description of these risks, uncertainties and other risks can be found in the Company’s regulatory filings with the French Autorité des Marchés Financiers (AMF), the Company’s Securities and Exchange Commission (SEC) filings and reports, including in the Company’s 2017 Document de Référence filed with the AMF in April 2018 and in the Company’s Annual Report on Form 20-F filed with the SEC on April 24, 2018 and future filings and reports by the Company. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements. ERYTECH disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in ERYTECH’s expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by law.

____________________
1 Hammel et al, Annals of Oncology (2017) 28 (suppl_5): v209-v268

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

Media Advisory: Bombardier to Report its First Quarter 2019 Financial Results and to Hold its Annual Meeting of Shareholders on Thursday, May 223.4.2019 22:54:00 CESTPressemelding

MONTRÉAL, April 23, 2019 (GLOBE NEWSWIRE) -- Bombardier (TSX: BBD.B) will publish its financial results for the first quarter of 2019 and hold its annual meeting of shareholders at the Grand Quay (former Alexandra Pier) located in Montréal’s Old Port on Thursday, May 2, 2019. Quarterly conference call On May 2 at 8:00 a.m., EDT, Bombardier’s management will hold a webcast/conference call intended for investors and financial analysts to review the company’s financial results for the first quarter of 2019. Please find below the dial-in information for the call: In English: 514 394 9320 or 1 866 240 8954 (toll-free in North America) +800 6578 9868 (overseas calls) In French: 514 394 9316 or (with translation) 1 888 791 1368 (toll-free in North America) +800 6578 9868 (overseas calls) Annual meeting of shareholders WHERE: Grand Quay, 200 de la Commune Street West, Montréal, Québec, H2Y 4B2 WHEN: Thursday, May 2, 2019 Media registration: 9:30 a.m. - 10:15 a.m. Eastern Daylight Time (EDT) Op

Patton Enhances Cloud Orchestration Service with OA&M Messaging23.4.2019 20:05:00 CESTPressemelding

Expanding its virtualized NMS with alerts and notifications sent to mobile teams, Patton reduces operational expense and complexity for service providers SmartNode VoIP… More than Just Talk! GAITHERSBURG, Md., April 23, 2019 (GLOBE NEWSWIRE) -- Patton Electronics—creator of SmartNode virtual VoIP CPE and CopperLink Ethernet and power-over-Ethernet extenders—has enhanced its revolutionary Patton Cloud virtualized edge-orchestration service by adding new alerts and notifications capabilities, the company announced today. WATCH the VIDEO TUTORIAL Patton Cloud Alerts and Notifications Added alerting and notification capabilities augment the Patton Cloud with fault and performance-monitoring tools for service-quality assurance, as well as device and service management. The Patton cloud already provides automated onboarding and provisioning as part of its full-service, life-cycle orchestration solution. Now, element status, statistics, faults, alerts, and alarms can all be delivered to techn

Continued Growth for INVNT Following Client Wins, An Expanded Offering, New Offices and Fresh Talent23.4.2019 15:20:00 CESTPressemelding

NEW YORK, NY, April 23, 2019 (GLOBE NEWSWIRE) -- INVNT, the global live brand storytelling agency™, achieved a number of milestones in 2018, a move that saw its revenues reach over $54 million, exceeding forecasts and representing a 30% increase on the previous year. With a number of impressive new clients and continued expansion in the works, the agency is targeting $62 million in revenue for 2019. INVNT secured new clients including Microsoft, Facebook, Pfizer, Xero, TEDxSydney, New Relic and Mary Kay last year. They grew many accounts from local to global, a move that now sees INVNTrs deliver campaigns for clients across the globe. INVNT also exceeded existing clients’ expectations in 2018, delivering compelling live brand storytelling™ moments for the likes of General Motors, Grant Thornton, Merck, PepsiCo, Samsung and Subway. Scott Cullather, CEO, INVNT explains: “Our tremendous growth is due to a combination of our team’s ability to develop compelling live brand stories that are

Always Powered by Passion: Meizu 16s Flagship Smartphone Unveiled, Snapdragon 855 and 48MP OIS Dual Camera23.4.2019 15:00:00 CESTPressemelding

Zhuhai, April 23, 2019 (GLOBE NEWSWIRE) -- Zhuhai, 23rd April 2019 -- Meizu Technology Co., Ltd (Meizu) has officially introduced its latest flagship 16s and will be available for sale in China on 28th April starting at 3198 RMB. The signature Meizu Design brings a sense of elegance to the phone. Powered by Qualcomm Snapdragon 855, the 16s features a 48MP + OIS Dual Camera, making it the best device to use for everyday shots. The latest flagship 16s is a testament to the 16 years’ experience in phone making of Meizu. The company has spared no effort with 100% dedication in producing premium phone for quality-seeking users, despite the size of the target market. 16s is a product that reflects ‘100% efforts for 1% selected Products’, Meizu strives for excellence with passion. Meizu 16s comes in Pearl White, Carbon Black, and Phantom Blue, of which 6+128G, 8+128G and 8+256G will be respectively priced at 3198 RMB, 3498 RMB and 3998 RMB, and will be available on Meizu official website for

iGrafx Announces Cohesive RPA Accelerator Solution23.4.2019 14:48:00 CESTPressemelding

Combines Core Capabilities from iGrafx, myInvenio, Servicetrace, UiPath and BP3 Global Dallas, TX, April 23, 2019 (GLOBE NEWSWIRE) -- Today at the iNNOVATE 2019 conference, iGrafx unveiled the industry’s first end-to-end RPA Accelerator solution, enabling enterprises to identify, assess, prioritize, execute and govern robotic process automation (RPA) projects. The turnkey package includes a new version of the iGrafx Platform, along with process mining from myInvenio, RPA bots from either UiPath or Servicetrace and professional services from BP3. For the first time ever, Center of Excellence leaders can access the combined, best-of-breed capabilities from a single source for a single price. “Our customers tell us that they have a huge challenge understanding what to optimize and automate in order to achieve real digital transformation,” said Ryan Tognazzini, CEO at iGrafx. This is a challenge that is also iterated again and again by industry experts. In a recent Forrester report, Rob Ko

MJBizDaily Introduces MJBizDaily European Cannabis Symposium, Copenhagen, Denmark, May 623.4.2019 11:00:00 CESTPressemelding

DENVER, April 23, 2019 (GLOBE NEWSWIRE) -- The producers of America’s oldest and largest cannabis trade show, Marijuana Business Conference & Expo (MJBizCon), introduce MJBizDaily’s European Cannabis Symposium in Denmark, Copenhagen. MJBizDaily’s European Cannabis Symposium will take place on Monday, May 6 at the Scandic Copenhagen Hotel in Copenhagen, Denmark. Leaders in the business, research and legislation of Europe’s medical marijuana and hemp market will gather for an intensive one-day conference offering educational sessions on the latest in tech, scientific research, and potential impacts on global markets. Table top exhibitors and an opening cocktail reception on Sunday, May 5 will also offer invaluable networking opportunities. “Regulated, normalized cannabis programs are just now starting to come into their own across Europe. As those government, industry and scientific ties continue to strengthen across the continent, the time is right to provide an in-person platform for e